China New Borun (BORN) Forms $1.39 Double Bottom; Profile of 3 Analysts Covering Biocept, Inc. (BIOC)

Among 3 analysts covering Biocept Inc (NASDAQ:BIOC), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Biocept Inc had 4 analyst reports since August 19, 2015 according to SRatingsIntel. Roth Capital initiated Biocept, Inc. (NASDAQ:BIOC) rating on Monday, June 6. Roth Capital has “Buy” rating and $1.20 target. The firm has “Buy” rating by H.C. Wainwright given on Wednesday, August 19. See Biocept, Inc. (NASDAQ:BIOC) latest ratings:

China New Borun Corporation (BORN) formed double bottom with $1.28 target or 8.00% below today’s $1.39 share price. China New Borun Corporation (BORN) has $35.76 million valuation. The stock 0.07% or $0 during the last trading session, reaching $1.39. It is down 18.92% since March 14, 2017 and is downtrending. It has underperformed by 35.62% the S&P500.

Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor DNA assays utilizing a standard blood sample. The company has market cap of $20.96 million. The companyÂ’s cancer assays provide information to oncologists and other physicians that enable them to select personalized treatment for their patients who have been diagnosed with cancer based on molecular drivers. It currently has negative earnings. It offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, and melanoma.

The stock increased 2.04% or $0.0066 during the last trading session, reaching $0.3296. About 3.37M shares traded or 83.70% up from the average. Biocept, Inc. (NASDAQ:BIOC) has declined 31.06% since March 14, 2017 and is downtrending. It has underperformed by 47.76% the S&P500.

Free Email Newsletter

Enter your email address below to get the latest news and analysts’ ratings for your stocks with our free daily email newsletter: